

# Ana Castro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1209685/publications.pdf>

Version: 2024-02-01

75  
papers

3,184  
citations

186209

28  
h-index

155592

55  
g-index

87  
all docs

87  
docs citations

87  
times ranked

3836  
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of leucocyte and platelet-rich fibrin in socket management and ridge preservation: a split-mouth, randomized, controlled clinical trial. <i>Journal of Clinical Periodontology</i> , 2016, 43, 990-999.	2.3	122
2	The amyloid fold of Gad m 1 epitopes governs IgE binding. <i>Scientific Reports</i> , 2016, 6, 32801.	1.6	21
3	Bioactive prenylated phenyl derivatives derived from marine natural products: novel scaffolds for the design of BACE inhibitors. <i>MedChemComm</i> , 2014, 5, 474-488.	3.5	6
4	Combined use of pharmacophoric models together with drug metabolism and genotoxicity <i>in silico</i> studies in the hit finding process. <i>Journal of Computer-Aided Molecular Design</i> , 2013, 27, 79-90.	1.3	1
5	5-Imino-1,2,4-Thiadiazoles: First Small Molecules As Substrate Competitive Inhibitors of Glycogen Synthase Kinase 3. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1645-1661.	2.9	76
6	Kinase activators as a novel class of antidiabetic agents. <i>Drug Discovery Today</i> , 2012, 17, 528-529.	3.2	3
7	New heteroaryl nitrones with spin trap properties: Identification of a 4-furoxanyl derivative with excellent properties to be used in biological systems. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 795-802.	1.4	25
8	The first enantioselective synthesis of palinurin. <i>Chemical Communications</i> , 2009, , 3252.	2.2	24
9	CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1349-1359.	2.6	33
10	Non-ATP competitive glycogen synthase kinase 3 $\beta$ (GSK-3 $\beta$ ) inhibitors: Study of structural requirements for thiadiazolidinone derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 495-510.	1.4	57
11	Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6193-6206.	1.4	20
12	Heteroaryl nitrones as Drugs for Neurodegenerative Diseases: Synthesis, Neuroprotective Properties, and Free Radical Scavenger Properties. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 6150-6159.	2.9	48
13	In Vivo Anti-Chagas Vinylthio-, Vinylsulfinyl-, and Vinylsulfonylbenzofuroxan Derivatives. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 6004-6015.	2.9	35
14	Glycogen Synthase Kinase-3 (GSK-3) Inhibitory Activity and Structure-Activity Relationship (SAR) Studies of the Manzamine Alkaloids. Potential for Alzheimer's Disease. <i>Journal of Natural Products</i> , 2007, 70, 1397-1405.	1.5	123
15	The Tautomerism of 5-Amino-1,2,4-Thiadiazole: An Experimental and Theoretical Study. <i>European Journal of Organic Chemistry</i> , 2007, 2007, 5603-5608.	1.2	2
16	Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of <i>Trypanosoma cruzi</i> growth: Synthesis, biological evaluation, and structure-activity relationships. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2768-2781.	1.4	43
17	Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1-12.	1.9	97
18	Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1644-1652.	1.4	128

#	ARTICLE	IF	CITATIONS
19	Targeting Beta-Amyloid Pathogenesis Through Acetylcholinesterase Inhibitors. <i>Current Pharmaceutical Design</i> , 2006, 12, 4377-4387.	0.9	187
20	Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6795-6802.	1.4	46
21	Donepezil-tacrine hybrid related derivatives as new dual binding site inhibitors of AChE. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6588-6597.	1.4	145
22	Good oral absorption prediction on non-nucleoside benzothiadiazine dioxide human cytomegalovirus inhibitors using combined chromatographic and neuronal network techniques. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 1919-1921.	1.0	6
23	SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives: Exploration of Structural Requirements for Glycogen Synthase Kinase 3 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 7103-7112.	2.9	114
24	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors. <i>Archiv Der Pharmazie</i> , 2005, 338, 18-23.	2.1	17
25	Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: Advances in the development of specific phosphodiesterase inhibitors. <i>Medicinal Research Reviews</i> , 2005, 25, 229-244.	5.0	111
26	Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors.. <i>ChemInform</i> , 2005, 36, no.	0.1	0
27	Cyclic Nucleotide Phosphodiesterases and Their Role in Immunomodulatory Responses: Advances in the Development of Specific Phosphodiesterase Inhibitors. <i>ChemInform</i> , 2005, 36, no.	0.1	0
28	Marine compounds for the therapeutic treatment of neurological disorders. <i>Expert Opinion on Therapeutic Patents</i> , 2005, 15, 1377-1386.	2.4	30
29	CODES/Neural Network Model: a Useful Tool for in Silico Prediction of Oral Absorption and Blood-Brain Barrier Permeability of Structurally Diverse Drugs. <i>QSAR and Combinatorial Science</i> , 2004, 23, 89-98.	1.5	34
30	Synthesis and nematocidal activity of S-glycopyranosyl-6,7-diarylthiolumazines. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 4431-4437.	1.4	6
31	Synthesis and muscarinic activities of O-[(Benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 2263-2268.	1.4	12
32	Benzothiadiazine dioxides (BTD) derivatives as non-nucleoside human cytomegalovirus (HCMV) inhibitors. study of structural requirements for biological activity. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 2395-2402.	1.4	5
33	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 1725-1732.	2.4	15
34	Benzothiadiazine Dioxide Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of Main Heterocycle Modified Derivatives. <i>Antiviral Chemistry and Chemotherapy</i> , 2003, 14, 107-114.	0.3	11
35	Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease-modifying agents. <i>Expert Opinion on Therapeutic Patents</i> , 2003, 13, 1725-1732.	2.4	5
36	First Non-ATP Competitive Glycogen Synthase Kinase 3 <sup>β</sup> (GSK-3 <sup>β</sup> ) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 1292-1299.	2.9	421

#	ARTICLE	IF	CITATIONS
37	Inhibitors of glycogen synthase kinase-3: future therapy for unmet medical needs?. Expert Opinion on Therapeutic Patents, 2002, 12, 1527-1536.	2.4	49
38	Non-Cholinergic Pharmacotherapy Approaches to the Future Treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2002, 2, 37-50.	1.1	33
39	Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medicinal Research Reviews, 2002, 22, 373-384.	5.0	302
40	CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors. European Journal of Medicinal Chemistry, 2001, 36, 333-338.	2.6	48
41	Recent strategies in the development of new human cytomegalovirus inhibitors. Medicinal Research Reviews, 2001, 21, 227-244.	5.0	27
42	Studies on the reactivity of some <i>N</i> -arylamines and <i>N</i> -heteroarylamines towards electrophilic reagents. Synthesis of new <i>N</i> -pyridylthioureas and thiazolines derivatives. Journal of Heterocyclic Chemistry, 2001, 38, 435-441.	1.4	2
43	Anti-HIV-1 Activity of Benzothiadiazine Dioxide. Antiviral Chemistry and Chemotherapy, 2001, 12, 347-351.	0.3	6
44	Peripheral and Dual Binding Site Acetylcholinesterase Inhibitors: Implications in treatment of Alzheimers Disease. Mini-Reviews in Medicinal Chemistry, 2001, 1, 267-272.	1.1	134
45	Reductive Cleavage of Potential Cholinomimetics Thiadiazolidinones: A New Family of Spiro Compounds. European Journal of Organic Chemistry, 2000, 2000, 675-680.	1.2	3
46	Lipase-catalysed synthesis of new acetylcholinesterase inhibitors: <i>N</i> -benzylpiperidine aminoacid derivatives. Bioorganic and Medicinal Chemistry, 2000, 8, 731-738.	1.4	11
47	<i>N</i> -Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitors. European Journal of Medicinal Chemistry, 2000, 35, 913-922.	2.6	78
48	Hindered Inversion/Rotation in Diheteroaryl Alkyl Amines with a <i>N</i> -(1-Pyrazolyl) Group: Dynamic NMR and Molecular Modelling Studies. Tetrahedron, 2000, 56, 1739-1743.	1.0	12
49	Novel agents for the treatment of human cytomegalovirus infection. Expert Opinion on Therapeutic Patents, 2000, 10, 165-177.	2.4	7
50	Inhibition of tau phosphorylation: a new therapeutic strategy for the treatment of Alzheimer's disease and other neurodegenerative disorders. Expert Opinion on Therapeutic Patents, 2000, 10, 1519-1527.	2.4	39
51	Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides: First Phosphodiesterase 7 Inhibitors. Journal of Medicinal Chemistry, 2000, 43, 683-689.	2.9	74
52	Benzothiadiazine Dioxide Dibenzyl Derivatives as Potent Human Cytomegalovirus Inhibitors: Synthesis and Comparative Molecular Field Analysis. Journal of Medicinal Chemistry, 2000, 43, 3218-3225.	2.9	27
53	Nonnucleoside Human Cytomegalovirus Inhibitors: Synthesis and Antiviral Evaluation of (Chlorophenylmethyl)benzothiadiazine Dioxide Derivatives. Journal of Medicinal Chemistry, 2000, 43, 3267-3273.	2.9	27
54	Chlorophenylmethyl benzothiadiazine dioxides derivatives: Potent human cytomegalovirus inhibitors. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 3133-3136.	1.0	10

#	ARTICLE	IF	CITATIONS
55	On the tautomerism of 2,1,3-benzothiadiazinone S,S-dioxide and related compounds. <i>Tetrahedron</i> , 1999, 55, 12405-12410.	1.0	12
56	Intramolecular oxidative cyclizations in heteroarylthioureas: A versatile pathway to bridgehead heterocyclic systems. <i>Journal of Heterocyclic Chemistry</i> , 1999, 36, 991-995.	1.4	12
57	Synthesis and Potential Muscarinic Receptor Binding and Antioxidant Properties of 3-(Thiadiazolyl)pyridine 1-Oxide Compounds. <i>Archiv Der Pharmazie</i> , 1999, 332, 191-194.	2.1	35
58	Regioselective Lipase-Catalysed Amidation of DicarboxylicN-Blocked Amino Acid Diesters – Effect of the Side-Chain Length. <i>European Journal of Organic Chemistry</i> , 1999, 1999, 2835-2839.	1.2	6
59	Novel Potential Agents for Human Cytomegalovirus Infection: Synthesis and Antiviral Activity Evaluation of Benzothiadiazine Dioxide Acyclonucleosides. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 1145-1150.	2.9	26
60	Synthesis of nonsymmetrically 3,4-disubstituted 1,2,5-thiadiazole dioxides. <i>Journal of Heterocyclic Chemistry</i> , 1998, 35, 297-300.	1.4	5
61	Phosphodiesterase inhibitory properties of losartan. design and synthesis of new lead compounds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1998, 8, 505-510.	1.0	58
62	The use of molecular similarity indices in the determination of a bioactive conformation. <i>European Journal of Medicinal Chemistry</i> , 1998, 33, 617-623.	2.6	2
63	Comparative Molecular Field Analysis (CoMFA) on [6] + [6] Fused Pyrazines with Nematocide Properties. <i>QSAR and Combinatorial Science</i> , 1997, 16, 372-376.	1.4	3
64	Arylimino-1,2,4-thiadiazolidinones: A new family of potassium channel openers. <i>Bioorganic and Medicinal Chemistry</i> , 1997, 5, 1275-1283.	1.4	19
65	Base promoted transformation on thiadiazolopyridinium chlorides. <i>Journal of Heterocyclic Chemistry</i> , 1997, 34, 337-340.	1.4	4
66	New Synthetic Route to of 1,2,4-Thiadiazolines and 1,3-Thiazolines via Thiadiazolopyridinium Salts. <i>Heterocycles</i> , 1996, 43, 2657.	0.4	10
67	Dioxides of bicyclic thiadiazines: a new family of smooth muscle relaxants. <i>Bioorganic and Medicinal Chemistry</i> , 1995, 3, 179-185.	1.4	14
68	Tautomerism of benzo- and cyclopenta-[1,2,6]thiadiazine S,S-dioxides. <i>Journal of the Chemical Society Perkin Transactions II</i> , 1994, , 1561-1564.	0.9	13
69	Thiadiazolopyridinium Salts: Intermediates for Heterocyclic Synthesis. <i>Heterocycles</i> , 1994, 38, 1737.	0.4	6
70	Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments. , 0, , 125-154.		34
71	The Crystal Structures of Glycogen Synthase Kinase 3. , 0, , 61-82.		1
72	GSK-3, a Key Player in Alzheimer's Disease. , 0, , 105-124.		0

#	ARTICLE	IF	CITATIONS
73	Protein Kinase Assays for Drug Discovery. , 0, , 189-201.		0
74	Marine Compounds as a New Source for Glycogen Synthase Kinase 3 Inhibitors. , 0, , 307-331.		4
75	TDZD's: Selective and ATP Noncompetitive Glycogen Synthase Kinase 3 Inhibitors. , 0, , 257-280.		2